Head-to-head evidence
GlyphAllo (allopregnanolone prodrug) vs KH607
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline
GlyphAllo (allopregnanolone prodrug) · SPT-300
Developed by PureTech Health and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07065240 (registry estimate)
KH607
Developed by Chengdu Kanghong Pharmaceutical
NCT07101120 · Phase 2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 126 participants, and used the clinical HAM-D17 score as its primary endpoint. However, the registry does not report whether the primary endpoint was met, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: December 2027 · NCT07741331 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GlyphAllo (allopregnanolone prodrug)'s landscape · KH607's landscape